Fig. 2From: First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s diseaseMean serum AAB-003 concentrations following initial intravenous infusions of increasing doses of AAB-003Back to article page